Deadline: 16-Aug-22
The Research Investment for Global Health Technology (RIGHT) Fund Foundation is pleased to announce the 2022 Product Development Award to support developing new or improved vaccines, therapeutics, biologics, or diagnostic platforms as global public good for prevention and control of infectious diseases that disproportionately affect the people in the Global South.
The RIGHT Fund focuses on infectious diseases that have a disproportionate burden of morbidity and mortality in low- and middle-income countries (LMICs) or diseases with a pandemic potential.
The RIGHT Fund supports innovation that will significantly improve the scalability of and equitable access to the health technologies across countries and regions via public procurement including innovation to reduce cost and to improve manufacturability, ease of operation, thermostability and/or environmental sustainability.
The RIGHT Fund supports deep collaboration between Korean and non-Korean institutions that enables an exchange of ideas and expertise in the spirit of allyship and mutual respect. They particularly welcome and encourage collaboration between Korean and LMIC institutions to ensure that health technology development effort is guided by the local insights about the health system and socioeconomic context
Award Type
- Target health conditions
- Infectious diseases that disproportionately affect the people in the Low- and Middle-Income Countries (LMICs) or diseases with a pandemic potential
- Development stage
- From or near the initiation of the clinical development or validation phase to regulatory approval and WHO prequalification (WHO PQ).
- Intervention types
- Vaccines, therapeutics/biologics, diagnostics
- Partnership requirement
- Must include a Korean entity
- Collaborative submission by multiple countries highly welcome and recommended
Award Information
Successful projects will be awarded up to 4 billion KRW per project to be conducted for up to 36 months.
Eligibility Criteria
- The RIGHT Fund reserves the right to determine the eligibility of applicants and public health priority among the submitted proposals at its discretion.
- The applicant team must include at least one Korean entity with the expertise to make a significant contribution to the project. Inclusion of nonKorean partner(s) especially those from the Global South is highly recommended.
- Korean entity
- Korean companies (or entities with a research facility in Korea)
- Not-for-profit research organizations and foundations
- Government research institutions
- Academic institutions
- Non-Korean entity
- Life Science/Healthcare companies
- Not-for-profit research organizations, foundations or product development partners
- Government research institutions
- Public health laboratories
- Academic institutions
For more information, visit RIGHT Fund.
For more information, visit https://rightfund.org/en/apply-for-funding/funding-opportunities/